Developing country

Hemophilia is an X linked hereditary bleeding disorder characterized by a deficiency of clotting factors, resulting in defective blood coagulation and recurrent bleeding episodes. Approximately 90 percent of severe hemophilia patients live in developing countries where access to adequate health care resources is limited. Conventional management primarily involves clotting factor infusion and physiotherapy, but the high cost of factor replacement therapy makes it difficult for many patients in countries like India to receive adequate treatment or prophylaxis. In addition, safe and effective pain management options are limited. In this context, the present study evaluated the efficacy of homoeopathic medicines in the management of bleeding episodes among hemophilia patients through a double blind placebo controlled trial. A total of 53 patients with Hemophilia A and B were initially treated with standard management along with placebo homoeopathic medicines for one year, followed by the same treatment combined with active homoeopathic medicines during the subsequent year. Outcomes were assessed by blind evaluators based on the frequency of bleeding episodes, duration of healing, requirement of clotting factors, and pain score ratings. Homoeopathic medicines were selected by experienced physicians based on constitutional and acute symptom presentation. The results demonstrated significant improvement in the frequency and severity of bleeding episodes, healing duration, pain scores, and reduction in the requirement of blood products. The findings suggest that individualized homoeopathic treatment may contribute to improved quality of life and reduced economic burden for hemophilia patients when used alongside standard medical care.